BMRA · Biomerica Inc
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern. Our future viability depends on the successful execution of our strategic plans, securing additional financing, and achieving profitable operations.”View the 10-K filed Aug 31, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 21, 2025; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMRA
this stock
Biomerica Inc
|
$10.10M | -11.9% | -16.2% | — | 0.4% |
|
ABT
Abbott Laboratories
|
$189.18B | -13.2% | +5.7% | 30.4 | 1.2% |
|
MDT
Medtronic plc
|
$118.37B | -3.1% | +8.4% | 22.8 | 1.1% |
|
SYK
Stryker Corp
|
$118.14B | -12.4% | +11.2% | 31.9 | 1.8% |
|
BSX
Boston Scientific Corp
|
$70.10B | -50.8% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 21, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMRA | +5.7% | +38.8% | +12.7% | +6.2% | -11.9% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | +5.4% | +38.2% | -4.1% | +5.4% | -25.3% |